Skip to main content

Advertisement

SpringerLink
Log in

Update on Biomarkers in Psoriatic Arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Biomarkers in psoriatic arthritis (PsA) may serve as surrogate end points for disease outcome and can provide insights into disease susceptibility and natural history. Biomarkers could relate to diagnosis, pathogenesis, prognosis, therapeutic response, and comorbidities. The “felt need” is, however, in the development of biomarkers for the presence of PsA in patients with psoriasis, as well as that for joint damage. During the past few years, many studies related to PsA biomarkers have been conducted. These studies are reviewed here. C-reactive protein, matrix metalloproteinase-3, and circulating osteoclast precursors show promise. An international goal-directed study to determine biomarkers for joint damage in PsA is now under way through a collaborative effort of GRAPPA (the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) and OMERACT (Outcome Measures for Rheumatology Clinical Trials).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89–95.

    Article  Google Scholar 

  2. Wright V, Moll JMH: Psoriatic arthritis. In Seronegative Polyarthritis. Amsterdam, The Netherlands: North Holland Publishing Co.; 1976:169–223.

    Google Scholar 

  3. Taylor W, Gladman D, Helliwell P, et al.; CASPAR Study Group: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665–2673.

    Article  PubMed  Google Scholar 

  4. Fitzgerald O, Winchester R: Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009, 11:214.

    Article  PubMed  Google Scholar 

  5. Gladman DD, Antoni C, Mease P, et al.: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005, 64(Suppl 2):ii14–ii17.

    Article  PubMed  Google Scholar 

  6. Gladman DD: Natural history of psoriatic arthritis. Baillieres Clin Rheumatol 1994, 8:379–394.

    Article  CAS  PubMed  Google Scholar 

  7. Fransen J, Antoni C, Mease PJ, et al.: Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006, 65:1373–1378.

    Article  CAS  PubMed  Google Scholar 

  8. Ho PY, Barton A, Worthington J, et al.: Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis 2008, 67:677–682.

    Article  CAS  PubMed  Google Scholar 

  9. Cargill M, Schrodi SJ, Chang M, et al.: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273–290.

    Article  CAS  PubMed  Google Scholar 

  10. • Nair RP, Duffin KC, Helms C, et al.; Collaborative Association Study of Psoriasis: Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009, 41:199–204. This article reports on the first large-scale genome-wide study to include PsA patients. Genetic associations with psoriasis, PsA, and differences between psoriasis and PsA are reported.

    Article  CAS  PubMed  Google Scholar 

  11. Rahman P, Inman RD, Maksymowych WP, et al.: Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol 2009, 36:137–140.

    CAS  PubMed  Google Scholar 

  12. Filer C, Ho P, Smith RL, et al.: Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008, 58:3705–3709.

    Article  CAS  PubMed  Google Scholar 

  13. Hüffmeier U, Lascorz J, Böhm B, et al.: Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol 2009, 129:355–358.

    Article  PubMed  Google Scholar 

  14. Liu Y, Helms C, Liao W, et al.: A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008, 4:e1000041.

    Article  PubMed  Google Scholar 

  15. Day TG, Ramanan AV, Hinks A, et al.: Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis. Arthritis Rheum 2008, 58:2142–2146.

    Article  CAS  PubMed  Google Scholar 

  16. Soto-Sánchez J, Santos-Juanes J, Coto-Segura P, et al.: Genetic variation at the CCR5/CCR2 gene cluster and risk of psoriasis and psoriatic arthritis. Cytokine 2010, 50:114–116.

    Article  PubMed  Google Scholar 

  17. Gladman DD, Farewell VT: The role of HLA antigens as indicators of progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995, 38:845–850.

    Article  CAS  PubMed  Google Scholar 

  18. Balding J, Kane D, Livingstone W, et al.: Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 2003, 48:1408–1413.

    Article  CAS  PubMed  Google Scholar 

  19. Rahman P, Snelgrove T, Peddle L, et al.: A variant of the IL4 I50V single-nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis. Arthritis Rheum 2008, 58:2207–2208.

    Article  PubMed  Google Scholar 

  20. Lascorz J, Hüffmeier U, Schulze-Koops H, et al.: Lack of genetic association of the interleukin-4 receptor single-nucleotide polymorphisms I50V and Q551R with erosive disease in psoriatic arthritis. Arthritis Rheum 2006, 54:4023–4024.

    Article  CAS  PubMed  Google Scholar 

  21. Seitz M, Wirthmüller U, Möller B, Villiger PM: The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007, 46:93–96.

    Article  CAS  Google Scholar 

  22. Chandran V, Siannis F, Rahman P, et al.: Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol 2010 (in press).

  23. Batliwalla FM, Li W, Ritchlin CT, et al.: Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med 2005, 11:21–29.

    Article  CAS  PubMed  Google Scholar 

  24. Stoeckman AK, Baechler EC, Ortmann WA, et al.: A distinct inflammatory gene expression profile in patients with psoriatic arthritis. Genes Immun 2006, 7:583–591.

    Article  CAS  PubMed  Google Scholar 

  25. • Grcevic D, Jajic Z, Kovacic N, et al.: Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol 2010, 37:246–256. This gene expression study on patients with PsA, ankylosing spondylitis, RA, and osteoarthritis and healthy controls reported the similarities and differences of peripheral blood expression profiles of bone-regulatory factors as markers of the form of arthritis, disease activity, and therapeutic responsiveness.

    Article  PubMed  Google Scholar 

  26. Gladman DD, Pollock R, Virtanen C, et al.: Microarray analyses of peripheral blood cells identifies gene expression profile that differentiates psoriatic arthritis (PsA) from psoriasis and controls. Arthritis Rheum 2009, 60:S537.

    Google Scholar 

  27. Ridker PM, Morrow DA: C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003, 21:315–325.

    Article  PubMed  Google Scholar 

  28. Tam LS, Tomlinson B, Chu TT, et al.: Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford) 2008, 47:718–723.

    Article  Google Scholar 

  29. • Strober B, Teller C, Yamauchi P, et al.: Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008, 159:322–330. The results from this randomized trial demonstrate that hsCRP elevation in patients with moderate to severe psoriasis is attributable to the presence of PsA as well as the degree of skin involvement.

    Article  CAS  PubMed  Google Scholar 

  30. Alenius GM, Eriksson C, Rantapää Dahlqvist S: Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol 2009, 27:120–123.

    PubMed  Google Scholar 

  31. Saxne T, Heinegard D: Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992, 31:583–591. (Published erratum appears in Br J Rheumatol 1993, 32:247.)

    Article  CAS  PubMed  Google Scholar 

  32. Skoumal M, Haberhauer G, Fink A, et al.: Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: a marker for unknown peripheral joint involvement? Clin Exp Rheumatol 2008, 26:1087–1090.

    CAS  PubMed  Google Scholar 

  33. Chandran V, Cook RJ, Edwin J, et al.: Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010 (in press).

  34. • Van den Bosch F, Manger B, Goupille P, et al.: Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010, 69:394–399. This large, open-label, uncontrolled study in PsA demonstrated that elevated CRP is a predictor for achieving an ACR 50 response with adalimumab.

    Article  PubMed  Google Scholar 

  35. Gratacós J, Casado E, Real J, Torre-Alonso JC: Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007, 66:493–497.

    Article  PubMed  Google Scholar 

  36. Chandran V, Shen H, Pollock R, et al.: Soluble biomarkers predict response to anti-tumour necrosis factor (TNF) therapy in psoriatic arthritis. Arthritis Rheum 2009, 60:S666.

    Google Scholar 

  37. • Kristensen LE, Gülfe A, Saxne T, Geborek P: Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008, 67:364–369. Results from a large biologics registry indicated that high CRP levels and concomitant MTX treatment are associated with longer treatment continuation of anti-TNF therapy in patients with PsA. The duration of treatment is a composite measure of drug effectiveness and encompasses factors such as adverse drug reactions, side effects, poor adherence, and loss of efficacy.

    Article  CAS  PubMed  Google Scholar 

  38. Ritchlin CT, Haas-Smith SA, Li P, et al.: Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821–831.

    CAS  PubMed  Google Scholar 

  39. • Anandarajah AP, Schwarz EM, Totterman S, et al.: The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008, 67:296–301. This study shows that OCP frequency decreases on treatment with etanercept but does not correlate with changes in bone edema and clinical parameters.

    Article  CAS  PubMed  Google Scholar 

  40. • Chiu YG, Shao T, Feng C, et al.: CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther 2010, 12:R14. This study found an elevated frequency of circulating CD14 + CD16 + cells in PsA patients compared with controls. The level of CD16 expression correlated with the bone resorption activity; thus, CD16 is a marker for OCPs. This study takes us one step closer to using OCP frequency as a biomarker for structural joint damage in clinical practice.

    Article  PubMed  Google Scholar 

  41. Pamuk GE, Nuri Pamuk O, Orüm H, et al.: Elevated platelet-monocyte complexes in patients with psoriatic arthritis. Platelets 2009, 20:493–497.

    Article  CAS  PubMed  Google Scholar 

  42. Sarma J, Laan CA, Alam S, et al.: Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002, 105:2166–2171.

    Article  PubMed  Google Scholar 

  43. Kruithof E, Baeten D, De Rycke L, et al.: Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005, 7:R569–R580.

    Article  CAS  PubMed  Google Scholar 

  44. • van Kuijk AW, Gerlag DM, Vos K, et al.: A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis 2009, 68:1303–1309. This study identified synovial biomarkers of response to treatment with adalimumab. The study design and results provide a framework for short proof-of-concept studies with newer biologic agents.

    Article  PubMed  Google Scholar 

  45. Lories RJ, Derese I, Luyten FP, de Vlam K: Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin Exp Rheumatol 2008, 26:96–102.

    CAS  PubMed  Google Scholar 

  46. Tan YM, Ostergaard M, Doyle A, et al.: MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage. Arthritis Res Ther 2009, 11:R2.

    Article  PubMed  Google Scholar 

  47. Marzo-Ortega H, McGonagle D, Rhodes LA, et al.: Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis 2007, 66:778–781.

    Article  CAS  PubMed  Google Scholar 

  48. Anandarajah AP, Ory P, Salonen D, et al.: Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging. Ann Rheum Dis 2010, 69:206–209.

    Article  CAS  PubMed  Google Scholar 

  49. Weckbach S, Schewe S, Michaely HJ, et al.: Whole-body MR imaging in psoriatic arthritis: additional value for therapeutic decision making. Eur J Radiol 2009 Jul 23 (Epub ahead of print).

  50. Raza N, Hameed A, Ali MK: Detection of subclinical joint involvement in psoriasis with bone scintigraphy and its response to oral methotrexate. Clin Exp Dermatol 2008, 33:70–73.

    CAS  PubMed  Google Scholar 

  51. • Ritchlin CT, Qureshi AA, de Vlam K, et al.: Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010, 37:462–467. This review describes the framework for a planned international initiative to identify biomarkers for structural joint damage in PsA.

    Article  PubMed  Google Scholar 

  52. Maksymowych WP, Landewé R, Tak PP, et al.: Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009, 36:1785–1791.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Dr. Chandran is supported by a Canadian Institutes of Health Research Clinical Research Initiative Fellowship, the Henry A. Beatty Scholarship from the University Health Network, and the Krembil Foundation.

Disclosure

Dr. Chandran has received honoraria from Wyeth, Abbott Laboratories, and Schering-Plough.

Dr. Gladman has received honoraria and/or grant support from Abbott Laboratories, Amgen, Bristol-Myers Squibb, Centocor Ortho Biotech, Schering-Plough, Wyeth, and Pfizer.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, 1E-410B, Toronto, Ontario, M5T 2S8, Canada

    Vinod Chandran & Dafna D. Gladman

Authors
  1. Vinod Chandran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dafna D. Gladman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dafna D. Gladman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chandran, V., Gladman, D.D. Update on Biomarkers in Psoriatic Arthritis. Curr Rheumatol Rep 12, 288–294 (2010). https://doi.org/10.1007/s11926-010-0107-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-010-0107-0

Keywords

Search

Navigation